appliedtherapeutics.com (APLT): Price-to-Sales Ratio

Corporate company logo of Applied Therapeutics (APLT)

Applied Therapeutics relies on ethical bioethics standards and pricing transparency. Business prospects depend on regulatory approval for rare pathology therapies. Complex inhibitor patents guarantee monopoly status, creating a significant barrier for competitors. The company's revenue valuation visualizes market expectations, and the value of 14.60 captures this metric, determining the balance between growth potential and investment risks.

APLT: Applied Therapeutics P/S Multiple 05/21/2023 - 02/16/2026

Metric breakdowns and analytics for Applied Therapeutics (APLT)

- share price and consensus valuation forecast:
Price Performance Chart Applied Therapeutics Inc.|APLT - Price Target Chart
- stock exchange capitalization data:
Market Valuation Applied Therapeutics|APLT - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Applied Therapeutics|APLT - Book Capitalization|Market Capitalization to Book Value Ratio appliedtherapeutics.com|APLT - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Applied Therapeutics|APLT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio appliedtherapeutics.com|APLT - Company Aggregate Debts|Debts to Book Capitalization Applied Therapeutics|APLT - Company Long-Term Debts|Company Short-Term Debts Applied Therapeutics|Critical Liquidity Ratio appliedtherapeutics.com
- earnings and valuation multiples information:
APLT - Company Net Income|Forward Earnings Applied Therapeutics|APLT - Price to Earnings Ratio|Future Price to Earnings Applied Therapeutics Inc.|APLT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Applied Therapeutics|APLT - Operating profit EBITDA|Net earnings per one share for the last twelve months Applied Therapeutics|APLT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months appliedtherapeutics.com|APLT - Net earnings per share growth this year|Expected earnings per share trend next year Applied Therapeutics
- issuer revenue and sales details:
APLT - Company Sales|Company Projected Revenue Volume appliedtherapeutics.com|APLT - P/S Multiple|Forward Price to Sales Applied Therapeutics
General company analysis:APLT Applied Therapeutics Inc.
Finished products of Applied Therapeutics, Inc.

Investors must identify an objective entry point based on the business's intrinsic value. The specialization of Applied Therapeutics (APLT) in treating rare diseases ensures stable demand and revenue resilience against market cycles. The company's P/S ratio reflects market capitalization relative to annual revenue, allowing for an assessment of whether the asset is overvalued. This indicator confirms the reliability of the investment by comparing the current price with the fundamental ability to generate cash flow.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - P/S Multiple|ABEO - P/S Multiple|mereobiopharma.com (MREO) - Price-to-Revenue Ratio|Price-to-Sales Ratio PLX (Protalix BioTherapeutics, Inc)|Price-to-Revenue Ratio Pliant Therapeutics Inc|aileronrx.com - Price-to-Sales Ratio|Price-to-Revenue Ratio Gelteq Limited (GELS)|Price-to-Revenue Ratio AYTU (aytubio.com)|P/S Multiple CMMB (Chemomab Therapeutics Ltd.)|Price-to-Revenue Coefficient SRx Health Solutions Inc (SRXH)|Polyrizon Ltd. - P/S Multiple|Price to Sales Aeterna Zentaris|CYTH: P/S Multiple|Market Cap to Revenue Ratio INZY|Market Cap to Revenue RPHM|CSCI: Market Capitalization-to-Revenue Ratio